Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• patients with acute BRVO with less than three month duration

Exclusion Criteria:

• vision less than 20/320 and vison more than 20/50

• duration more than 3 months

• history of glaucoma and diabetic retinopathy

• any media opacity that prevent funduscopy